Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on PK/PD of HIP1601 in Healthy Volunteers
NCT03882112Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Apr 2019
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of esomeprazole strontium in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Hanmi Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at 24 hours and Area Under the Curve to Last Measurable Concentration at 24 hours. Started Apr 2019; status: completed.
02
Drugs
esomeprazole strontium
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03882112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03882112.